Breast Cancer Research and Treatment

Papers
(The H4-Index of Breast Cancer Research and Treatment is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Intraoperative assessment of axillary sentinel lymph nodes by telepathology87
Prognostic and predictive impact of NOTCH1 in early breast cancer85
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia82
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy68
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis68
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe67
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients56
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial56
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study52
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990–2019: an examination using estimates from the global burde46
Endocrine adherence in male versus female breast cancer: a seer-medicare review44
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial44
Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials44
Area deprivation index and breast cancer outcomes among patients in Western New York41
The feasibility and safety of fasting-mimicking diet in breast cancer patients with chemotherapy in China41
Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer36
Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study36
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival35
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study31
Surveillance mammography after treatment for male breast cancer31
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy31
Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis30
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer29
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study29
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience29
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers29
Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients28
Integrating SENOMAC and AMAROS: a call for de-escalation28
0.14069199562073